Genetic factors of thrombosis <i>FII G20210A</i>, <i>FV G1691A</i> (<i>Arg506Gln</i>) in patients with thoracoabdominal malignant tumors
Introduction. Malignant tumor is one of the leading factors of venous and arterial thrombosis. But there is no data on the need for a genetic testing protocol of cancer patients for genetic predisposition thrombotic conditions, despite the fact that a number of polymorphisms of hemostasis genes are...
Saved in:
| Main Authors: | A. A. Korolyova, S. S. Gerasimov, L. N. Lyubchenko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-04-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/653 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of FV G1691A, FV H1299R, and FII G20210A variations with thrombosis and coronary artery disease (CAD): A population-based study
by: Ünallı Özmen Sevda, et al.
Published: (2025-01-01) -
Factor V Leiden (R506Q), Prothrombin G20210A, and MTHFR C677T Variants and Thrombophilia in Qatar Biobank Participants: A Case Control Study
by: Sapha Shibeeb, et al.
Published: (2024-10-01) -
Management of pregnancy and labor in female with combination of homozygous Leiden and heterozygous prothrombin G20210A mutations
by: M. O. Arslanbekova, et al.
Published: (2020-04-01) -
FV Leiden, Prothrombin II, and MTHFR C677T Mutations in Children and Young Adults with Thromboembolic Diseases
by: Sura O. AL-Dewachi, et al.
Published: (2024-12-01) -
Antiphospholipid antibodies, genetic thrombophilia and fetal growth retardation
by: E. A. Orudzhova
Published: (2022-01-01)